Trial Profile
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms PERSIST-5
- Sponsors Novartis; Novartis Pharmaceuticals
- 02 Jun 2017 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 27 Feb 2017 Planned End Date changed from 1 May 2018 to 30 Apr 2017.